Skip to main content

Table 5 Associations between HER3 protein expression and clinicopathological characteristics

From: Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

Characteristic BCA cohort HER2-amplified BCA cohort
HER3-m (%) p HER3-c (%) p HER3-t (%) p HER3-m (%) p HER3-c (%) p HER3-t (%) p
- + - + - + - + - + - +
HER2 status    0.615    0.990    0.882          
 Negative 85.8 83.8   84.6 84.7   84.2 84.9           
 Positive 14.2 16.2   15.4 15.3   15.8 15.1           
Estrogen receptor status    0.057    0.280    0.839    0.013*    0.376    0.104
 Negative 23.6 15.1   30.8 18.7   18.4 19.5   54.3 31.7   46.7 35.2   46.5 32.8  
 Positive 76.4 84.9   69.2 81.3   81.6 80.5   45.7 68.3   53.3 64.8   53.5 67.2  
Progesterone receptor status    0.002**    0.368    0.443    0.888    0.882    0.716
 Negative 43.2 26.4   46.2 34.0   38.2 33.3   57.1 58.5   60.0 58.0   55.8 59.0  
 Positive 56.8 73.6   53.8 66.0   61.8 66.7   42.9 41.5   40.0 42.0   44.2 41.0  
Triple-negativity (HER2-/ER-/PR-)    0.000***    0.099    0.798          
 No 83.8 96.2   76.9 90.8   89.5 90.5           
 Yes 16.2 3.8   23.1 9.2   10.5 9.5           
Histological grade    0.121    0.855    0.705    0.435    0.767    0.956
 I-II 72.8 81.4   75.0 77.3   75.4 77.8   28.6 22.3   26.7 23.3   23.3 23.6  
 III 27.2 18.6   25.0 22.7   24.6 22.2   71.4 77.7   73.3 76.7   76.7 76.4  
Ki-67 proliferation index    0.597    0.985    0.852    0.475    0.213    0.658
 Low 73.4 70.2   71.4 71.7   72.7 71.4   22.9 17.6   6.7 19.8   20.9 17.9  
 High 26.6 29.8   28.6 28.3   27.3 28.6   77.1 82.4   93.3 80.2   79.1 82.1  
Histological type    0.629    0.359    0.204    0.055    0.940    0.960
 Ductal 55.5 58.2   69.2 56.4   63.2 54.8   85.3 94.8   93.3 92.8   92.7 92.9  
 Lobular 44.5 41.8   30.8 43.6   36.8 45.2   14.7 5.2   6.7 7.2   7.3 7.1  
Lymph nodal status    0.531    0.637    0.716    0.232    0.169    0.035*
 Negative pN0 58.3 61.9   66.7 59.9   62.0 59.5   65.7 54.5   40.0 58.4   42.9 61.4  
 Positive pN+ 41.7 38.1   33.3 40.1   38.0 40.5   34.3 45.5   60.0 41.6   57.1 38.6  
Tumor size (TNM stage)    0.840    0.921    0.781    0.173    0.001***    0.368
 pT1-pT2 91.9 91.3   92.3 91.5   90.8 91.8   88.6 94.9   73.3 95.5   90.7 94.6  
 pT3-pT4 8.1 8.7   7.7 8.5   9.2 8.2   11.4 5.1   26.7 4.5   9.3 5.4  
Tumor size (cm)    0.003**    0.834    0.357    0.643    0.014*    0.143
 <2cm 21.6 42.7   28.6 32.4   26.7 34.1   51.7 46.9   15.4 51.2   37.1 51.4  
 ≥2cm 78.4 57.3   71.4 67.6   73.3 65.9   48.3 53.1   84.6 48.8   62.9 48.6  
Patient age at diagnosis    0.726    0.624    0.217    0.069    0.000***    0.156
 <50 years 21.6 20.0   15.4 21.0   15.8 22.4   31.4 17.6   60.0 16.7   27.9 17.9  
 ≥50 years 78.4 80.0   84.6 79.0   84.2 77.6   68.6 82.4   40.0 83.3   72.1 82.1  
Cytokeratin 5/14 expression             0.583    0.561    0.006**
 Negative           85.3 88.7   92.9 87.6   76.2 92.0  
 Positive           14.7 11.3   7.1 12.4   23.8 8.0  
Basal phenotype (CK5/14+, ER-)             0.191    0.801    0.001***
 No           85.3 92.5   92.9 90.8   78.6 95.2  
 Yes           14.7 7.5   7.1 9.2   21.4 4.8  
  1. p-values from Pearson’s Chi-Square test, statistically significant values are underlined and marked with symbols *p<0.05, **p≤0.01, and ***p≤0.001. Percentages of breast carcinomas presented according to membranous (−m), cytoplasmic (−c), and total (−t) HER3 expression; −/+ means low/high HER3 expression by IHC